IGF-1 and the Liver: Your Growth Factor Factory

Liver Peptide Hormones

75% of circulating IGF-1

Hepatocytes are the dominant source of circulating IGF-1, producing approximately three-quarters of the serum supply under growth hormone stimulation.

Aguiar-Oliveira et al., Physiology, 2026

Aguiar-Oliveira et al., Physiology, 2026

View as image

Every time your pituitary gland releases a pulse of growth hormone, your liver responds by producing insulin-like growth factor 1. This 70-amino-acid polypeptide, known as IGF-1, mediates most of growth hormone's effects on tissues throughout the body: muscle growth, bone lengthening, organ development, and metabolic regulation. The liver produces approximately 75% of the IGF-1 circulating in your blood, making hepatocytes the body's primary IGF-1 factory.^[1] Understanding this hepatic production system explains why liver disease crashes IGF-1 levels, why growth hormone deficiency has metabolic consequences far beyond short stature, and why the GH-IGF-1 axis is a target for peptide therapeutics. For a broader look at the metabolic hormones your liver produces, see our pillar article on FGF21.

The GH-IGF-1 Axis: From Brain to Liver

The production of IGF-1 by the liver is not autonomous. It is part of a multi-organ endocrine cascade that begins in the hypothalamus and ends with IGF-1 acting on target tissues throughout the body.

The hypothalamus releases growth hormone-releasing hormone (GHRH), which stimulates the anterior pituitary to secrete growth hormone (GH) in pulsatile bursts. Somatostatin, also from the hypothalamus, inhibits GH release between pulses. Ghrelin from the stomach provides a third input, amplifying GH secretion through the GHS receptor.^[1] The pulsatile pattern matters: hepatocytes respond more strongly to intermittent GH exposure than to continuous levels, which is why GH therapeutics are designed to mimic natural pulsatility.

When a GH pulse reaches the liver, GH binds to growth hormone receptors (GHR) on hepatocyte surfaces. GHR is a type I cytokine receptor that signals through the JAK2 (Janus kinase 2) and STAT5 (signal transducer and activator of transcription 5) pathway. JAK2 phosphorylation activates STAT5, which translocates to the nucleus and directly drives transcription of the IGF1 gene. The resulting IGF-1 protein is secreted into the hepatic sinusoids and enters the systemic circulation.

This pathway is not solely GH-dependent. Insulin, delivered to the liver via the portal vein at concentrations much higher than systemic levels, is a critical co-regulator. Portal insulin enhances GHR expression on hepatocytes and potentiates GH-stimulated IGF-1 production. This insulin-GH interaction explains why patients with type 1 diabetes (insulin-deficient) or insulin resistance have altered IGF-1 levels despite normal GH secretion.^[2]

IGF-1 then feeds back to the hypothalamus and pituitary, suppressing further GH release. This negative feedback loop keeps the system in balance: high IGF-1 suppresses GH, low IGF-1 allows GH to rise. Disruption of this feedback, through liver disease, malnutrition, or genetic mutations, destabilizes the entire axis. The connection between how GHRH and somatostatin regulate GH pulsatility is explored in our sermorelin article. For the role of ghrelin as a GH secretagogue, see our GHRP-6 article.

Why the Liver Dominates IGF-1 Production

Nearly every tissue in the body can produce IGF-1 locally (autocrine/paracrine production), including muscle, bone, brain, and kidney. The liver's dominance is a matter of scale: hepatocytes are large cells with extensive protein-synthesis machinery, the liver receives the highest concentration of portal GH (directly from the pituitary drainage), and GHR density on hepatocytes is among the highest of any cell type.

Landmark mouse studies using liver-specific IGF-1 gene deletion showed that removing hepatic IGF-1 production reduced circulating IGF-1 by approximately 75%, confirming the liver as the source of three-quarters of blood IGF-1.^[1] The surprise finding: these mice grew normally despite dramatically reduced serum IGF-1. Local tissue IGF-1 production was sufficient for postnatal growth, indicating that circulating (endocrine) IGF-1 and tissue-derived (autocrine/paracrine) IGF-1 have distinct functional roles.

Circulating liver-derived IGF-1 appears to be more important for metabolic regulation, feedback inhibition of GH, and protection against insulin resistance than for direct growth stimulation. Campos et al. (2026) studied the Itabaianinha cohort in Brazil, individuals with congenital isolated GH deficiency due to a GHRH receptor mutation. These patients have IGF-1 levels reduced by over 90%, severe short stature, and central obesity, but their tissues still produce local IGF-1, which partially compensates for the absence of hepatic production.^[3]

How IGF-1 Travels in the Blood: Binding Proteins

Less than 1% of circulating IGF-1 is free. The vast majority is bound to one of six IGF-binding proteins (IGFBPs), with IGFBP-3 carrying approximately 80% of circulating IGF-1 in a ternary complex with the acid-labile subunit (ALS). Both IGFBP-3 and ALS are also produced primarily by the liver under GH stimulation.

This binding system serves multiple functions. It extends IGF-1's half-life from approximately 10 minutes (free form) to 12-15 hours (IGFBP-3 complex), creating a stable circulating reservoir that smooths out the pulsatile nature of GH-driven IGF-1 secretion into a more constant signal. It prevents the insulin-like hypoglycemic effects that free IGF-1 would cause at the concentrations present in blood, since bound IGF-1 cannot activate insulin receptors. And it delivers IGF-1 to specific tissues by releasing it in contexts where IGFBP-3 is cleaved by local proteases at sites of tissue injury, inflammation, or active remodeling.

The clinical significance of this binding system is direct. Measuring total IGF-1 (free plus bound) in blood is the standard biomarker for GH status. Low total IGF-1 confirms GH deficiency; high total IGF-1 suggests GH excess (acromegaly). But total IGF-1 reflects hepatic production capacity, not necessarily what the tissues are seeing. The ratio of free to bound IGF-1, determined by IGFBP levels, adds nuance that simple total IGF-1 measurements miss.

Bowers et al. (2004) demonstrated the practical relevance of this system by showing that 30-day continuous infusion of the GH-releasing peptide GHRP-2 in older adults elevated not just GH and IGF-1 but also IGFBP-3 and IGFBP-5 concentrations.^[4] The coordinated increase in IGF-1 and its binding proteins reflected the liver's integrated response to sustained GH stimulation, producing both the growth factor and its transport/regulatory system. For a detailed comparison of how different GH-releasing peptides like GHRP-2 and GHRP-6 affect this axis, see our comparison article.

The Age-Related Decline: Somatopause

GH secretion decreases by approximately 14% per decade after age 30, and serum IGF-1 falls in parallel. This age-related decline in the GH-IGF-1 axis, sometimes called the somatopause, contributes to reduced muscle mass, increased fat mass, decreased bone density, and impaired immune function in older adults.

Frutos et al. (2007) investigated the mechanisms behind this decline and the ability of GH secretagogues to reverse it.^[5] They found that the aging hypothalamus produces more somatostatin (which inhibits GH) and less GHRH (which stimulates GH), shifting the balance toward suppression. GH secretagogues, which activate GH release through the ghrelin receptor pathway, can bypass this somatostatin brake and partially restore GH pulsatility and IGF-1 levels in older adults.

The dopaminergic system also plays a role. De Gennaro et al. (2025) showed that dopamine D2 receptor signaling modulates both GHRH and somatostatin neuronal activity, providing another regulatory input to the GH-IGF-1 axis that changes with aging.^[6] The oral GH secretagogue MK-677 (ibutamoren) targets this axis through the ghrelin receptor to elevate IGF-1 in aging populations.

The practical question is whether restoring youthful IGF-1 levels in older adults produces clinical benefit. GH replacement therapy in GH-deficient adults increases lean mass, decreases fat mass, and improves bone density. But GH therapy in otherwise-healthy older adults with age-related GH decline has produced mixed results: modest improvements in body composition offset by side effects including edema, joint pain, carpal tunnel syndrome, and glucose intolerance. The distinction between pathological GH deficiency (where replacement is clearly beneficial) and physiological age-related decline (where the risk-benefit ratio is uncertain) drives much of the ongoing research into CJC-1295 and IGF-1 elevation and other peptide approaches that aim to restore the axis more physiologically than direct GH injection.

When the Liver Fails: IGF-1 and Liver Disease

Because the liver is the primary IGF-1 source, liver disease directly impairs IGF-1 production. This creates a pathological cycle: the damaged liver produces less IGF-1, which removes the negative feedback on GH secretion, leading to elevated GH levels that further stress the diseased liver.

Stanley et al. (2021) examined IGF-1 and IGFBP relationships in nonalcoholic fatty liver disease (NAFLD) and found that hepatic IGF-1 expression correlated inversely with disease severity.^[7] Patients with more severe NAFLD and fibrosis had lower IGF-1 and IGFBP-3 levels. The relationship was independent of GH levels, indicating that the liver's ability to respond to GH was impaired, not just the GH signal itself.

The consequences of reduced hepatic IGF-1 in NAFLD extend beyond the liver. Lower circulating IGF-1 removes feedback inhibition on pituitary GH secretion, leading to elevated GH levels. While this might seem compensatory, chronically elevated GH in the setting of a GH-resistant liver promotes lipolysis and insulin resistance in peripheral tissues, worsening the metabolic syndrome that often accompanies NAFLD. The result is a paradox: patients with fatty liver disease have high GH but low IGF-1, and both abnormalities contribute to disease progression.

In cirrhosis, the IGF-1 deficit is even more severe. Cirrhotic patients may have IGF-1 levels 50-80% below normal, and serum IGF-1 correlates with the Child-Pugh score for liver function. This has led to interest in IGF-1 as a biomarker for liver disease severity and a potential therapeutic target for hepatic regeneration.

In a separate study, Stanley et al. (2021) tested whether restoring the GH-IGF-1 axis with tesamorelin (a GHRH analogue) could improve hepatic outcomes in individuals with HIV-infection and NAFLD.^[8] Tesamorelin increased pulsatile GH secretion, which raised hepatic IGF-1 production and reduced circulating markers of immune activation while improving hepatic immune pathways. This demonstrated that restoring the hormonal input to a damaged liver could partially normalize its IGF-1 output and downstream metabolic effects. Badran et al. (2026) confirmed these findings in a meta-analysis of randomized controlled trials, showing that tesamorelin reduced hepatic fat and improved body composition in HIV-associated lipodystrophy.^[9]

IGF-1 Beyond Growth: Metabolic and Neuroprotective Roles

The name "insulin-like growth factor" reflects IGF-1's structural similarity to insulin (approximately 50% amino acid sequence homology) and its ability to bind the insulin receptor at high concentrations. But IGF-1's roles extend well beyond growth.

Aguiar-Oliveira et al. (2026) reviewed IGF-1's actions in the brain, finding that GH stimulates hepatic IGF-1 production which then crosses the blood-brain barrier to exert neuroprotective effects.^[1] In the brain, IGF-1 promotes neuronal survival, synaptic plasticity, and myelination through activation of the PI3K/Akt and MAPK/ERK signaling pathways. Low circulating IGF-1 (whether from aging, liver disease, or GH deficiency) is associated with cognitive decline, depression, and increased risk of neurodegenerative diseases including Alzheimer's.

This brain connection highlights an often-overlooked consequence of liver disease: hepatic dysfunction that reduces circulating IGF-1 may impair cognitive function through reduced neuroprotective signaling, independent of the well-known hepatic encephalopathy that occurs in advanced liver failure. The liver's role as the body's primary IGF-1 source thus has implications that extend from bone growth to brain health to metabolic regulation. The other major hepatokine peptides your liver produces also have metabolic signaling roles, but IGF-1 remains the best-characterized endocrine output of the GH-liver axis.

The cancer connection adds complexity. Higher circulating IGF-1 levels are epidemiologically associated with increased risk of certain cancers (breast, prostate, colorectal), because IGF-1 promotes cell proliferation and inhibits apoptosis.^[10] Albini et al. (2025) reviewed how antidiabetic and anti-obesity drugs that reduce IGF-1 signaling (including GLP-1 agonists) may have cancer-preventive effects. This dual nature of IGF-1, essential for normal growth and tissue maintenance but potentially promoting cancer when chronically elevated, is one reason that interventions targeting the GH-IGF-1 axis require careful calibration rather than simple maximization. The therapeutic window is real: too little IGF-1 causes growth failure, metabolic dysfunction, and neurodegeneration; too much promotes malignant cell growth and organ enlargement. Finding the optimal range, and maintaining it through peptide-based approaches that work with rather than override the body's feedback systems, remains the central challenge in this field.

The Bottom Line

The liver is the body's primary IGF-1 factory, producing approximately 75% of circulating supply under growth hormone stimulation via the JAK2/STAT5 signaling pathway. This hepatic IGF-1 serves endocrine functions (metabolic regulation, GH feedback, neuroprotection) distinct from the autocrine/paracrine IGF-1 produced locally by tissues for growth. Liver disease directly impairs IGF-1 production, creating pathological cycles in NAFLD and cirrhosis. Age-related GH decline reduces hepatic IGF-1 output, contributing to somatopause. GH secretagogues and GHRH analogues can partially restore this axis, but the cancer-promoting potential of elevated IGF-1 means interventions must be carefully calibrated.

Frequently Asked Questions

Why does the liver produce most of the body's IGF-1?

Hepatocytes produce approximately 75% of circulating IGF-1 because they have high growth hormone receptor density, extensive protein-synthesis capacity, and receive the highest concentration of GH via portal blood from the pituitary. When GH binds hepatic GH receptors, it activates the JAK2/STAT5 pathway, driving IGF-1 gene transcription and secretion into the bloodstream (Aguiar-Oliveira et al., 2026).

What happens to IGF-1 when the liver is damaged?

Liver disease reduces IGF-1 production because damaged hepatocytes cannot respond normally to growth hormone signaling. Stanley et al. (2021) found that hepatic IGF-1 expression correlates inversely with NAFLD severity and fibrosis stage. The resulting IGF-1 deficiency may worsen insulin resistance, promote muscle wasting, and remove feedback inhibition on GH, leading to elevated GH levels that further stress the liver.

Does IGF-1 decline with age?

Yes. GH secretion decreases approximately 14% per decade after age 30, and hepatic IGF-1 production falls in parallel. This age-related decline, called somatopause, contributes to reduced muscle mass, increased body fat, decreased bone density, and impaired immunity. Frutos et al. (2007) showed that the decline is driven by increased hypothalamic somatostatin and decreased GHRH, shifting the balance toward GH suppression.

How does growth hormone stimulate IGF-1 production?

Growth hormone binds to GH receptors on hepatocyte surfaces, activating the JAK2 kinase, which phosphorylates STAT5. Activated STAT5 enters the nucleus and drives transcription of the IGF-1 gene. Portal insulin from the pancreas enhances this process by upregulating GH receptor expression. The liver responds most strongly to pulsatile GH delivery, which is why natural GH secretion occurs in bursts rather than continuously.

Can you increase IGF-1 levels naturally?

IGF-1 levels are influenced by sleep quality (GH is released during deep sleep), exercise intensity (resistance training stimulates GH pulses), protein intake (amino acids stimulate GH), and liver health. Adequate sleep, regular strength training, and sufficient dietary protein support the GH-IGF-1 axis. Conversely, chronic caloric restriction, poor sleep, excessive alcohol, and liver disease all reduce hepatic IGF-1 production.

Is high IGF-1 dangerous?

Chronically elevated IGF-1 is associated with increased risk of certain cancers (breast, prostate, colorectal) because IGF-1 promotes cell proliferation and inhibits apoptosis. Albini et al. (2025) reviewed this cancer connection. The pathological extreme is acromegaly, where a GH-secreting pituitary tumor drives excessive IGF-1 production. The dual nature of IGF-1, essential for health at normal levels but potentially harmful when chronically elevated, is why therapeutic interventions target restoration to normal ranges rather than maximization.